Actively Recruiting
TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)
Led by Tempus AI · Updated on 2026-04-02
200
Participants Needed
11
Research Sites
346 weeks
Total Duration
On this page
Sponsors
T
Tempus AI
Lead Sponsor
A
AstraZeneca
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.
CONDITIONS
Official Title
TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed small cell lung cancer diagnosis
- Diagnosis made with excisional or core needle biopsy specimen (fine needle aspirate may be permitted with approval)
- Tumor sample available before first-line therapy and/or before second-line therapy if applicable
- ECOG performance status of 0 to 2 at enrollment
- Planned or prior extensive stage first-line therapy with etoposide, platinum, and PD-L1 inhibitor (atezolizumab or durvalumab)
- Completion of standard first-line therapy before second-line therapy if applicable
- Extensive stage disease at diagnosis per NCCN definition
- Willing and able to provide informed consent
- Palliative radiotherapy allowed with measurable disease outside radiation area
You will not qualify if you...
- Secondary malignancy diagnosed less than 3 years ago or treated less than 3 years ago, except certain low-risk skin cancers
- Mixed small cell and non-small cell lung cancer histology
- Small cell cancers from other organs or suspected metastases without lung primary
- Large Cell Neuroendocrine cancers
- Carcinoid or atypical carcinoid tumors
- Transformed small cell lung cancer after targeted NSCLC therapy
- Treatment with investigational immunotherapy agents other than PD-1 or PD-L1 inhibitors
- Unwillingness to provide additional blood samples
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States, 90720
Withdrawn
2
University of Colorado
Aurora, Colorado, United States, 80045
Actively Recruiting
3
Illinois Cancer Care
Peoria, Illinois, United States, 61615
Actively Recruiting
4
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
5
Englewood Health Medical Center
Englewood, New Jersey, United States, 07631
Withdrawn
6
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
7
TriHealth Cancer Institute
Cincinnati, Ohio, United States, 45220
Actively Recruiting
8
Ohio State University
Columbus, Ohio, United States, 43210
Actively Recruiting
9
OhioHealth Research Institute
Columbus, Ohio, United States, 43214
Withdrawn
10
Oklahoma Cancer Specialists and Research Institutes
Tulsa, Oklahoma, United States, 74146
Withdrawn
11
Cancer Care Association of York
York, Pennsylvania, United States, 17403
Actively Recruiting
Research Team
S
Sculptor Study
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here